CLOs on the Move

Clover Biopharmaceuticals

www.cloverbiopharma.com

 
Founded in 2007, we are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases. Our vision is to empower humanity with a healthier future through transformative science. Our mission is to leverage the Trimer-Tag™ technology platform and manufacturing capabilities for the discovery, development and commercialization of novel vaccines and biologic therapies.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Neuromed Pharmaceuticals

Neuromed Pharmaceuticals Ltd. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ParaPRO

ParaPRO is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evoke Pharmaceuticals

Evoke Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Headway

Headway.co is a digital marketing agency that offers holistic services to help businesses scale their growth. From innovative digital strategies to custom web design and development, Headway.co specializes in conversion optimization and delivering meas...

La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.